Biogen: approval for Friedreich's ataxia in the EU
Skyclarys is the first treatment indicated in the European Union for this rare, genetic, disabling and life-shortening neurological disease. The treatment has demonstrated benefits for patients, compared to a placebo.
'Our team is committed to working with the medical community and health authorities across the EU to enable urgent access to treatment for patients,' says Priya Singhal, Biogen's Global Head of Development.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction